Format

Send to

Choose Destination
BMC Psychiatry. 2016 Nov 15;16(1):398.

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Author information

1
Research Center "The Great Senescence", University of Catania, Catania, Italy. giulia.malaguarnera@live.it.
2
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. giulia.malaguarnera@live.it.
3
Department of Experimental and Clinical Medicine, University of Catania, Catania, Italy.
4
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
5
Research Center "The Great Senescence", University of Catania, Catania, Italy.
6
U.O.C Physical Medicine and Rehabilitation, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy.
7
Department of Drug Sciences, University of Catania, Catania, Italy.
8
IRCCS Associazione Oasi Maria S.S., Institute for Research on Mental Retardation and Brain Aging, Troina, Italy.

Abstract

BACKGROUND:

Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg-IFN) and Ribavirin (RBV).

METHODS:

Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg-IFN plus RBV and placebo, while Group B received the same dosage of Peg-IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI).

RESULTS:

The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01).

CONCLUSIONS:

The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg-IFN and RBV.

TRIAL REGISTRATION:

NCT01957319 , First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered).

KEYWORDS:

Anxiety; Depression; Hepatitis C; Interferon; Silybin; Work ability index

PMID:
27842532
PMCID:
PMC5109776
DOI:
10.1186/s12888-016-1115-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center